TINUBU-SQUARE
Tinubu Square, a leading provider of credit insurance, surety and trade finance solutions, is launching today the Tinubu Bonding Insurance Suite (BIS), which has been developed to serve the surety bonding needs of insurers. The new product is a natural extension of Tinubu Square’s SaaS-based, end-to-end enterprise platform, used widely to help the industry manage and develop its international trade credit insurance, and now its surety bonding activities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190710005425/en/
The new Tinubu BIS is designed to support surety carriers in their digital transformation journey and to help them to adopt the technologies they need to become more agile and enhance their value proposition to customers.
It draws on Tinubu Square’s long-standing experience delivering solutions that enable insurers to administer the lifecycle of their products from commercial and risk underwriting to claims payment. The same dedication to improving visibility and delivering results has been written into the Bonding Insurance Suite. This will give insurers optimum time to market in what is often a fast moving environment requiring innovative risk distribution strategies. The new solution will allow them to manage an increasing number of bond wordings and signature processes.
Olivier Placca, Tinubu Square Deputy CEO, said: “Tinubu has grown a large and loyal customer base amongst international insurance companies. So, it has become incumbent on us to provide cutting-edge solutions that will support the industry’s business models profitably while helping insurers manage customer-focused strategies. The Bonding Insurance Suite is an extension of our existing, proven software, so it offers opportunities to digitize transactions and take advantage of data assets. It will also ensure that companies are equipped for fluctuating regulations and the particular demands of operating in multiple geographical locations. We have built our considerable knowledge and technical know-how into this new suite and this will be to the advantage of the surety bonding sector during the challenges they face in their digital transformation.”
Key features of the Tinubu Bonding Insurance Suite include:
- Administration – The capability to manage users, their permissions and authorities within the system. Organisational changes and new staff on-boarding can be easily managed with the profile management tool. Products and their parameters can be created and administered in defined bond categories and associated to bond wordings in the bond library. The suite also includes repository of intermediaries and financial counter-parties to help manage the distribution and production network.
- Commercial Underwriting – The central repository allows financial statements to be edited or uploaded in Tinubu’s proprietary pivot format and to interface with data providers. Bonding facilities and single bond submissions can be swiftly created, and users will find all the necessary information to manage their customer relationships efficiently.
- Risk Underwriting – All submission, customer data and diary records are easily accessed, including past assessments and decisions. Thanks to the pdf generator, decision making support material can be created and archived. Dedicated features in the suite allow exposure at the customer level to be aggregated and construction contract execution to be monitored while analysis can be performed across portfolios thanks to Tinubu’s structured data capture of customer, obligee and intermediary information.
User Experience Benefits : Forms and applications can be easily imported into the application and files uploaded in a variety of format using drag and drop. Tinubu has also embedded a diary to centralise documents and archive communications at various levels. Insurers will find that they can give access to their international teams in one single solution available in English, French and Spanish.
About Tinubu Square
Founded in 2000, Tinubu Square is a software vendor, enabler of the Credit Insurance, Surety and Trade Finance digital transformation. Tinubu Square enables organizations across the world to significantly reduce their exposure to risk and their financial, operational and technical costs with best-in-class technology solutions and services. Tinubu Square provides SaaS solutions and services to different businesses including credit insurers, receivables financing organizations and multinational corporations. Tinubu Square has built an ecosystem of customers in over 20 countries worldwide and has a global presence with offices in Paris, London, New York, Montreal and Singapore. For more information: www.tinubu.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190710005425/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom